Compare FNLC & MOBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNLC | MOBI |
|---|---|---|
| Founded | 1864 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 384.5M | 366.1M |
| IPO Year | 1995 | 2026 |
| Metric | FNLC | MOBI |
|---|---|---|
| Price | $34.60 | $14.42 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 25.7K | ★ 94.5K |
| Earning Date | 04-22-2026 | N/A |
| Dividend Yield | ★ 5.19% | N/A |
| EPS Growth | ★ 26.34 | N/A |
| EPS | ★ 0.80 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $42.56 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.13 | $12.66 |
| 52 Week High | $34.50 | $14.40 |
| Indicator | FNLC | MOBI |
|---|---|---|
| Relative Strength Index (RSI) | 80.68 | N/A |
| Support Level | $28.08 | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 1.30 | 0.00 |
| MACD | 0.53 | 0.00 |
| Stochastic Oscillator | 99.01 | 0.00 |
First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services, including deposit accounts and consumer, commercial, and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.
Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. The company develops, markets and sells devices for the treatment of medical conditions. Its flagship device is the Vivistim Paired Vagus Nerve Stimulation system, which is used to support motor function rehabilitation in patients with chronic ischemic stroke. The company generates all of its revenue from the sale of the Vivistim System to customers, mainly primary and comprehensive stroke centers, in the United States.